v3.26.3
Acquisitions - Preliminary Purchase Price Allocation (Details) - USD ($)
$ in Millions
May 14, 2026
Sep. 30, 2026
Dec. 31, 2025
Business Combination [Line Items]      
Goodwill*   $ 6,992.6 $ 6,491.1
Total assets acquired and liabilities assumed $ 0.0    
Apellis Pharmaceuticals, Inc.      
Business Combination [Line Items]      
Cash and cash equivalents 310.7    
Accounts receivable 384.4    
Inventory* 681.0    
Other current assets 46.1    
Operating lease assets 12.5    
Accounts payable (32.9)    
Accrued expense and other (118.4)    
Operating lease liabilities (18.1)    
Other, net (0.9)    
Total identifiable net assets 4,906.6    
Goodwill* 503.5    
Total assets acquired and liabilities assumed 5,410.1    
Inventory (31.0)    
Accrued expense and other (1.0)    
Total identifiable net assets (2.0)    
Goodwill* 2.0    
Apellis Pharmaceuticals, Inc. | Previously Reported      
Business Combination [Line Items]      
Cash and cash equivalents 310.7    
Accounts receivable 384.4    
Inventory* 712.0    
Other current assets 46.1    
Operating lease assets 12.5    
Accounts payable (32.9)    
Accrued expense and other (117.4)    
Operating lease liabilities (18.1)    
Total identifiable net assets 4,908.6    
Goodwill* 501.5    
Total assets acquired and liabilities assumed 5,410.1    
Apellis Pharmaceuticals, Inc. | Senior secured term loan      
Business Combination [Line Items]      
Long-term debt (395.2)    
Deferred tax liability (523.4)    
Deferred tax liability, measurement period adjustment (1.3)    
Apellis Pharmaceuticals, Inc. | Senior secured term loan | Previously Reported      
Business Combination [Line Items]      
Long-term debt (395.2)    
Deferred tax liability (522.1)    
Apellis Pharmaceuticals, Inc. | Convertible note      
Business Combination [Line Items]      
Long-term debt (101.5)    
Apellis Pharmaceuticals, Inc. | Convertible note | Previously Reported      
Business Combination [Line Items]      
Long-term debt (101.5)    
Other, net (0.9)    
Apellis Pharmaceuticals, Inc. | Completed Technology      
Business Combination [Line Items]      
Intangible assets 4,630.0    
Apellis Pharmaceuticals, Inc. | Completed Technology | Previously Reported      
Business Combination [Line Items]      
Intangible assets 4,630.0    
Apellis Pharmaceuticals, Inc. | In-process research and development      
Business Combination [Line Items]      
Intangible assets 32.3 $ 32.3  
Intangible asset 31.3    
Apellis Pharmaceuticals, Inc. | In-process research and development | Previously Reported      
Business Combination [Line Items]      
Intangible assets $ 1.0